BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | 0.45 | -0.30 | 2.45 |
| FCF Yield | -3.42% | -8.45% | -7.65% | -5.83% |
| EV / EBITDA | 178.88 | -16.24 | -17.87 | -21.11 |
| Quality | ||||
| ROIC | -0.71% | -26.41% | -33.59% | -37.00% |
| Gross Margin | 97.28% | 98.09% | 97.03% | 94.88% |
| Cash Conversion Ratio | 0.59 | 0.42 | 0.65 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.50% | 28.23% | 147.74% | 47.64% |
| Free Cash Flow Growth | 45.39% | 40.37% | -12.91% | -4.95% |
| Safety | ||||
| Net Debt / EBITDA | 57.52 | -6.34 | -3.04 | -0.73 |
| Interest Coverage | -0.03 | -0.96 | -1.50 | -3.00 |
| Efficiency | ||||
| Inventory Turnover | 1.52 | 0.16 | 0.24 | 0.46 |
| Cash Conversion Cycle | -41.79 | 672.75 | 797.58 | -535.52 |